Immunotherapeutic approach with oligodeoxynucleotides containing CpG motifs (CpG-ODN) in malignant glioma.
Bacterial DNA and synthetic oligodeoxynucleotides containing CpG motifs (CpG-ODNs) are strong activators of both innate and specific immunity, driving the immune response towards the Th1 phenotype. In cancer patients, CpG-ODNs can be used to activate the innate immunity and trigger a tumor-specific immune response. Several clinical trials are on-going worldwide in various cancers. In this chapter, we will focus on the potential applications of CpG-ODNs in glioma. So far, CpG-ODN has mainly been used by intratumoral injections. Indeed, human gliomas display a locally invasive pattern of growth and rarely metastasize, making local treatment clinically relevant.
Service de Neurologie, Hôpital Avicenne, Bobigny, France.
Renata
R
Ursu
Antoine F
AF
Carpentier
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D001932:Brain Neoplasms / Q000188:drug therapy / Q000276:immunology* / Q000378:metabolism; D002986:Clinical Trials as Topic; D018899:CpG Islands / Q000276:immunology*; D016207:Cytokines / Q000276:immunology / Q000378:metabolism; D005910:Glioma / Q000188:drug therapy / Q000276:immunology* / Q000378:metabolism; D006801:Humans; D007113:Immunity, Innate / Q000187:drug effects / Q000276:immunology; D009838:Oligodeoxyribonucleotides / Q000276:immunology* / Q000627:therapeutic use; D016019:Survival Analysis
D000276:Adjuvants, Immunologic; C408982:CPG-oligonucleotide; D016207:Cytokines; D009838:Oligodeoxyribonucleotides